Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for IMP761 (LAG-3 agonist) in Autoimmune disease. The expected timing is based on the latest available company guidance and may change.
07/30/26:- IMP761 Ph1 SAD met safety endpoint; additional trial updates remain expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.